Loading stock data…
Heron Therapeutics, Inc. (HRTX)
$0.44+0.01 (+1.28%)
Market ClosedLast close Jun 29
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Heron Therapeutics, Inc. in the Healthcare sector is trading at $0.44 with a market capitalization of $82M. Wall Street consensus targets $2.00 (1 analysts), implying a +359.2% move over the next 12 months. The stock is currently near its 52-week low of $0.38, remaining 59.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +359.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $34.71M↓ | $40.59M↑ | $38.21M↑ | $37.20M↓ | $38.90M |
| Gross Profit | $24.07M↓ | $29.47M↑ | $26.30M↓ | $27.34M↓ | $30.45M |
| Operating Income | -$4.76M↓ | $38,000↑ | -$4.09M↓ | -$1.64M↓ | $3.15M |
| Net Income | -$8.11M↓ | -$2.95M↑ | -$17.50M↓ | -$2.38M↓ | $2.63M |
Peer Comparison
JNJUNHPFE
Fundamentals
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, w...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$82.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-338.63%
Volume
Today's trading volume
1.99M
Recent News
Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision
The recent reset in the analyst fair value estimate for Heron Therapeutics, from US$4.75 to US$3.00 per share, has put the stock’s price target under fresh scrutiny. This shift lines up with fast changing views after the Cinvanti patent decision, where analysts are weighing legal risk and revenue concentration against the company’s appeal efforts and earnings guidance. Read on to see how to track these moving pieces and stay on top of the evolving Heron Therapeutics story. Analyst Price...
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% an
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?
We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Heron Therapeutics, Inc. (NASDAQ:HRTX) is another of the best penny stocks on this list. TheFly reported on May 11 that HRTX saw its price target reduced to $4 from $6 while the Buy rating was reiterated in a recent research […]
Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges
Heron Therapeutics Inc (HRTX) reports strong recovery and strategic expansions despite weather-related setbacks and competitive pressures.